Liarozole, an Inhibitor of Retinoic Acid Metabolism, Retarded Atherogenesis in LDLR-/- Mice

Authors

  • Noa Zolberg Relevy 1The Bert W. Strassburger Lipid Center; Sheba Medical Center, Tel-Hashomer, 5265601 Israel. 2Sackler Faculty of Medicine, Tel-Aviv University, Israel
  • Ayelet Harari 1The Bert W. Strassburger Lipid Center; Sheba Medical Center, Tel-Hashomer, 5265601 Israel. 2Sackler Faculty of Medicine, Tel-Aviv University, Israel
  • Yehuda Kamari 1The Bert W. Strassburger Lipid Center; Sheba Medical Center, Tel-Hashomer, 5265601 Israel. 2Sackler Faculty of Medicine, Tel-Aviv University, Israel
  • Dror Harats 1The Bert W. Strassburger Lipid Center; Sheba Medical Center, Tel-Hashomer, 5265601 Israel. 2Sackler Faculty of Medicine, Tel-Aviv University, Israel
  • Aviv Shaish The Bert W. Strassburger Lipid Center; Sheba Medical Center, Tel-Hashomer, 5265601 Israel.

DOI:

https://doi.org/10.7439/ijbar.v6i4.1634

Keywords:

squamous, metaplastic, radical mastectomy

Abstract

Liarozole is a Retinoic Acid Metabolism Blocking Agent (RAMBA). As retinoic acid (RA) and its precursor, beta-carotene (BC), have been shown to inhibit atherosclerosis development in mouse models, in the present study we investigated whether liarozole can mimic the anti-atherogenic effect of RA. We demonstrate, by using the LDL receptor-knockout mouse model fed a high-fat diet, that liarozole significantly reduces by 50% the aortic sinus atherosclerotic lesion area.

Downloads

Download data is not yet available.

References

Zhou B, Pan Y, Hu Z, Wang X, Han J, et al. (2012) All-trans-retinoic acid ameliorated high fat diet-induced atherosclerosis in rabbits by inhibiting platelet activation and inflammation. J Biomed Biotechnol 2012: 259693.

Langmann T, Liebisch G, Moehle C, Schifferer R, Dayoub R, et al. (2005) Gene expression profiling identifies retinoids as potent inducers of macrophage lipid efflux. Biochim Biophys Acta 1740: 155-161.

Demmig-Adams B, Adams WW, 3rd (2002) Antioxidants in photosynthesis and human nutrition. Science 298: 2149-2153.

Downloads

Published

2015-04-30

Issue

Vol. 6 No. 4 (2015): Apr

Section

Short Communication

License

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).

How to Cite

Liarozole, an Inhibitor of Retinoic Acid Metabolism, Retarded Atherogenesis in LDLR-/- Mice. (2015). International Journal of Biomedical and Advance Research, 6(4), 377-378. https://doi.org/10.7439/ijbar.v6i4.1634
Crossref
Scopus
Google Scholar
Europe PMC